Annual report pursuant to Section 13 and 15(d)

License, Clinical Trial and Sponsored Research Agreements (Details Textual)

v3.19.1
License, Clinical Trial and Sponsored Research Agreements (Details Textual) - USD ($)
1 Months Ended 12 Months Ended
Aug. 02, 2018
Jul. 03, 2017
Nov. 30, 2017
Nov. 20, 2017
May 31, 2017
Mar. 17, 2017
Feb. 28, 2017
Oct. 31, 2016
Apr. 30, 2015
Mar. 31, 2015
Dec. 31, 2018
Dec. 31, 2017
Mar. 17, 2018
Jan. 03, 2018
Nov. 28, 2017
Dec. 31, 2016
Payment Of Upfront Fees         $ 600,000                      
Revenue Recognition Milestone Method Payments Due $ 13,500,000       14,900,000                      
Research And Development Expense, Sponsored Research Payment                             $ 800,000  
Research and Development Expense                     $ 2,100,000          
Stock Issued During Period, Value, Purchase of Assets                       $ 1,682,000        
Proceeds from Issuance of Private Placement               $ 10,000,000                
Common Stock, Shares Authorized                     50,000,000 50,000,000        
Research and development - licenses acquired                     $ 3,360,000 $ 12,433,000        
Cost of Goods and Services Sold         50,000                      
UCLA License [Member]                                
Research and Development Expense                     100,000 100,000        
Research and development - licenses acquired                     0 200,000        
Psca Technology License [Member]                                
Payment Of Upfront Fees         300,000                      
Revenue Recognition Milestone Method Payments Due         14,900,000                      
Research and development - licenses acquired                     0 300,000        
Cost of Goods and Services Sold         50,000                      
Cs Technology License [Member]                                
Payment Of Upfront Fees         600,000                      
Revenue Recognition Milestone Method Payments Due         14,900,000                      
Research and development - licenses acquired                     0 600,000        
Cost of Goods and Services Sold         $ 50,000                      
IL13Ra2 [Member]                                
Research and Development Expense                     1,100,000 1,400,000        
Harvard College License [Member]                                
Payment Of Upfront Fees     $ 300,000                          
Other Commitment, Due in Next Twelve Months       $ 25,000                        
Other Commitment, Due in Third Year       100,000                        
Other Commitment, Due in Second Year       50,000                        
Development Milestones Method Additional Payments Due       16,700,000                        
Cost of Goods and Services Sold       $ 25,000                        
Sponsored Research Agreement [Member]                                
Research and Development Expense                     2,000,000 2,000,000        
CD123 CRA [Member]                                
Research and Development Expense                     800,000 1,400,000        
St Jude XSCID [Member]                                
Research and development - licenses acquired                     1,000,000 0        
Cost of Goods and Services Sold $ 100,000                              
University of California [Member]                                
Development Milestones Method Additional Payments Due           $ 14,300,000                    
University of California [Member] | UCLA License [Member]                                
Payment Of Upfront Fees           200,000                    
Other Commitment, Due in Next Twelve Months           15,000                    
Other Commitment, Due in Fifth Year           50,000                    
Other Commitment, Due in Fourth Year           $ 25,000                    
City Of Hope [Member]                                
Payment Of Upfront Fees             $ 100,000                  
Revenue Recognition Milestone Method Payments Due             100,000                  
Research And Development Expense, Sponsored Research Payment                           $ 900,000    
City Of Hope [Member] | Intellectual Property [Member]                                
Payment Of Upfront Fees                 $ 2,000,000              
Revenue Recognition Milestone Method Payments Due                       2,000,000        
City Of Hope [Member] | Intellectual Property [Member] | Maximum [Member]                                
Royalty Expense                       1,000,000        
City Of Hope [Member] | Commitment Two [Member] | Intellectual Property [Member]                                
Development Milestones Method Additional Payments Due                   $ 14,500,000            
City Of Hope [Member] | AR CD123 License [Member]                                
Revenue Recognition Milestone Method Payments Due             14,500,000                  
City Of Hope [Member] | IL License [Member]                                
Cost of Goods and Services Sold             25,000                  
City Of Hope [Member] | Spacer License [Member]                                
Cost of Goods and Services Sold             10,000                  
City Of Hope [Member] | IL13Ra2 [Member]                                
Payment Of Upfront Fees             9,300                  
Revenue Recognition Milestone Method Payments Due             14,500,000                  
Research And Development Expense, Sponsored Research Payment             200,000                  
Licensing Arrangements Additional Costs Incurred             100,000                  
Cost of Goods and Services Sold             25,000                  
City Of Hope [Member] | CD123 CRA [Member]                                
Payment Of Upfront Fees             19,450                  
Research And Development Expense, Sponsored Research Payment             200,000                  
Licensing Arrangements Additional Costs Incurred             $ 97,490                  
City Of Hope [Member] | Patent and Know-how Rights [Member]                                
Research And Development Expense, Sponsored Research Payment                           $ 75,000    
Fred Hutchinson Cancer Research Center [Member]                                
Research And Development Expense, Sponsored Research Payment                         $ 600,000      
Fred Hutchinson Cancer Research Center [Member] | CD20 Technology License [Member]                                
Payment Of Upfront Fees   $ 300,000                            
Development Milestones Method Additional Payments Due   39,100,000                            
Cost of Goods and Services Sold   50,000                            
Fred Hutchinson Cancer Research Center [Member] | CD20 Clinical Agreement [Member]                                
Research And Development Expense, Sponsored Research Payment   $ 5,300,000                            
Research and Development Expense                     $ 1,300,000 600,000        
Common Class A [Member]                                
Stock Issued During Period, Value, Purchase of Assets                       $ 0        
Common Stock, Shares Authorized                               1,000,000
Common Class A [Member] | City Of Hope [Member]                                
Stock Issued During Period, Shares, Purchase of Assets               293,588                
Common Class A [Member] | City Of Hope [Member] | Valuation, Market Approach [Member]                                
Stock Granted During Period, Value Per Share Determined               $ 5.73                
Stock Issued During Period, Value, Purchase of Assets               $ 1,700,000                
Common Class A [Member] | City Of Hope [Member] | Intellectual Property [Member]                                
Research and Development Expense                   $ 1,000,000            
Stock Granted During Period, Valuation Inputs, Weighted Marketability Rate                   44.80%            
Stock Granted During Period, Valuation Inputs, Weighted Average Cost of Capital                   30.00%            
Common Class A [Member] | City Of Hope [Member] | Intellectual Property [Member] | Discounted Cash Flow Model [Member]                                
Stock Granted During Period, Value Per Share Determined                   $ 0.147            
Stock Issued During Period, Value, Purchase of Assets                   $ 100,000